EVANSTON, Ill.--(BUSINESS WIRE)--Northfield Laboratories Inc. (Nasdaq: NFLD) announced today that its contract research organization has informed the Company that the report of the summary data from its pivotal Phase III trauma trial with PolyHeme®, the Company’s human-hemoglobin based oxygen-carrying red cell substitute, will not be complete until May.
